<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413322</url>
  </required_header>
  <id_info>
    <org_study_id>PXD101-CLN-4</org_study_id>
    <nct_id>NCT00413322</nct_id>
  </id_info>
  <brief_title>Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onxeo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onxeo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with
      advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor
      activity, and how the study drug behaves within the body when given with 5-Fluorouracil
      (5-FU).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Single-arm dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belinostat</intervention_name>
    <description>300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1</description>
    <arm_group_label>Single-arm dose escalation</arm_group_label>
    <other_name>PXD101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5-FU)</intervention_name>
    <description>250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.</description>
    <arm_group_label>Single-arm dose escalation</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed solid tumors

          -  Advanced colorectal cancer or other adenocarcinomas

          -  Tumor progression after standard chemotherapy, or where none yet approved

          -  At least one unidimensionally measurable lesion

          -  Karnofsky performance &gt;= 70%

          -  Life expectancy of at least 3 months

          -  Age &gt;= 18 years

          -  Signed, written Institutional Review Board (IRB)-approved informed consent

          -  Acceptable liver function:

               -  Bilirubin &lt;= 1.5 x upper limit of normal (ULN)

               -  AST (SGOT) and ALT (SGPT) &lt;= 2.5 x ULN, OR

               -  AST (SGOT) and ALT (SGPT) &lt;= 5 x ULN if liver metastasis

          -  Acceptable renal function:

               -  Serum creatinine within normal limits, OR

               -  Calculated creatinine clearance of &gt;= 60 mL/min/1.73 m2 for certain patients

          -  Acceptable hematologic status:

               -  Absolute neutrophil count (ANC) &gt;= 1500 cells/mm3

               -  Platelet count &gt;= 100,000 (plt/mm3)

               -  Hemoglobin &gt;= 9 g/dL

          -  Urinalysis: No clinically significant abnormalities

          -  Acceptable coagulation status:

               -  Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits, OR

               -  For patients on anticoagulation therapy, status within therapeutic range

          -  For men and women of child-producing potential, use of effective contraception

          -  Tumors accessible for needle biopsy

        Exclusion Criteria:

          -  Significant cardiovascular disease.

          -  A marked baseline prolongation of QT/QTc interval

          -  Long QT syndrome

          -  Required use of medication on dosing days that may cause torsade de pointes.

          -  Infections requiring intravenous (IV) systemic therapy

          -  Pregnant or nursing women

          -  Treatment with chemotherapy or investigational therapy &lt; 4 weeks (28 days) prior to
             study entry (6 weeks for nitrosoureas, mitomycin C, or Avastin).

          -  Treatment with radiation therapy or surgery either within 2 weeks prior to study
             entry, or not yet recovered if 2-4 weeks prior to study entry.

          -  Unwillingness or inability to comply with protocol procedures.

          -  Known active uncontrolled infection with HIV, hepatitis B, or hepatitis C

          -  Serious nonmalignant disease (e.g. hydronephrosis, liver failure, or other conditions)
             that could compromise protocol objectives in the opinion of the investigator and/or
             the sponsor

          -  Concurrent use of other investigational agent(s)

          -  Serious concurrent medical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Topotarget A/S</last_name>
    <role>Study Chair</role>
    <affiliation>Onxeo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Regional Hospital Hematology/Oncology Clinic</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid tumor</keyword>
  <keyword>Adenosarcoma</keyword>
  <keyword>Androgen-independent prostate cancer</keyword>
  <keyword>belinostat</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>bladder neoplasms</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Carcinoma, Small Cell</keyword>
  <keyword>Carcinosarcoma</keyword>
  <keyword>Chondrosarcoma</keyword>
  <keyword>Coin Lesion, Pulmonary</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Facial Neoplasms</keyword>
  <keyword>Fibrosarcoma</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>Hemangiosarcoma</keyword>
  <keyword>Histiocytoma, Malignant Fibrous</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>Leiomyosarcoma</keyword>
  <keyword>Liposarcoma</keyword>
  <keyword>lung cancer</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>Lymphangiosarcoma</keyword>
  <keyword>mesothelioma</keyword>
  <keyword>mesothelioma, cystic</keyword>
  <keyword>Mixed Tumor, Mesodermal</keyword>
  <keyword>Mouth Neoplasms</keyword>
  <keyword>Myosarcoma</keyword>
  <keyword>Myxosarcoma</keyword>
  <keyword>Osteosarcoma</keyword>
  <keyword>Otorhinolaryngologic Neoplasms</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Pancoast's Syndrome</keyword>
  <keyword>Parathyroid Neoplasms</keyword>
  <keyword>Phyllodes Tumor</keyword>
  <keyword>Pulmonary Sclerosing Hemangioma</keyword>
  <keyword>sarcoma</keyword>
  <keyword>thyroid cancer</keyword>
  <keyword>Thyroid Neoplasms</keyword>
  <keyword>Tracheal Neoplasms</keyword>
  <keyword>PXD101</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Belinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

